A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00793585|
Recruitment Status : Completed
First Posted : November 19, 2008
Results First Posted : July 1, 2011
Last Update Posted : May 25, 2016
|Condition or disease||Intervention/treatment||Phase|
|IgA Nephropathy||Drug: allopurinol Other: continue their usual therapy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective, Randomized Controlled Study of Uric Acid on the Progression of IgA Nephropathy|
|Study Start Date :||July 2007|
|Actual Primary Completion Date :||June 2009|
|Actual Study Completion Date :||June 2009|
Allopurinol group:allopurinol, 100-300mg/d according to the levels of Scr(serum creatinine) and UA(uric acid), for those Scr < 1.5mg/dl (133 umol/L) at the baseline, allopurinol was given 100 mg three times daily.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level < 6mg/dl , the dosage changed to 200mg/d.
Control group:(patient in this group were received health education and were encouraged to adhere to a low-purine diet and continue their usual therapy.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
Other: continue their usual therapy
Patients will receive lifestyle modification and continue their usual therapy.
- Change in Renal Function as Measured With eGFR [ Time Frame: baseline and 6 months ]
- The Longitudinal Change in Proteinuria and Blood Pressure(Including Changes in Antihypertensive Drugs Dosing). [ Time Frame: baseline and 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00793585
|The 1st Affiliated Hospital, Sun Yet-sen University|
|GuangZhou, Guangdong, China, 510080|
|Principal Investigator:||Xueqing Yu, M.D. & Ph.D.||1st Affiliated Hospital, Sun Yat-Sen University|